The Endocrinology Market in 2026

Endocrinology is one of the few medical specialties where demand is outrunning supply on every measure that matters to a new practice. The global endocrinology market was valued at about $46.2 billion in 2025 and is forecast to reach roughly $75 billion by 2035 (Wiseguy / Market Research Future, 2025). The drug side of the category is larger still: the US endocrinology drugs market alone is projected to grow from $78.6 billion in 2025 to $132.4 billion by 2032, a 7.7% compound annual rate (Mobility Foresights, 2025).

The reason a business plan should care about drug-market growth is that it pulls patients into specialist chairs. The same forces driving prescriptions, rising type 2 diabetes, an obesity epidemic now treated pharmacologically, and a steady load of thyroid disease, are the forces that fill an appointment book. The global endocrinology drugs market is estimated at $107.79 billion in 2025, climbing to $144.86 billion by 2030 (Mordor Intelligence, 2025).

The supply side is where a new entrant finds its opening. The US carries a shortfall of roughly 1,500 adult and 100 pediatric full-time-equivalent endocrinologists, and without an increase in fellows trained the adult gap is projected to widen to about 2,700 (Journal of Clinical Endocrinology & Metabolism, 2014). In plain terms, new-patient wait lists in many metros run six to twelve weeks. A focused practice that solves access, fast new-patient slots, structured diabetes and obesity programs, telehealth follow-ups, does not have to fight for demand. It has to manage it.

A credible plan names where the demand actually comes from. For most new practices it splits across three patient lines: diabetes (type 1, type 2, and gestational), thyroid and parathyroid disorders, and a fast-growing obesity-medicine line built around GLP-1 receptor agonists. Digital-first competitors such as Paloma Health, Steady Health and 9amHealth have proven that patients will pay for structured endocrine care delivered partly online, and their existence is a signal, not a threat, for a clinician who can offer both the relationship and the in-person work-up those platforms cannot.

Who the Patients Are

The mistake most first plans make is describing the market as "anyone with a hormone problem." Lenders and partners want a sharper picture, because the patient mix dictates payer mix, scheduling, and the staffing model. A focused endocrinology practice usually plans around four identifiable segments, each with a different acquisition path and a different margin.

• Established type 2 diabetes patients, the volume backbone, mostly referred by primary care, billing predominantly Medicare and commercial E/M plus continuous glucose monitor and remote-monitoring lines. High retention, recurring revenue, steady margin.
• Thyroid and nodule patients, episodic but referral-rich, often involving ultrasound and fine-needle aspiration once volume supports in-house imaging. A strong word-of-mouth and primary-care referral driver.
• Obesity-medicine / GLP-1 patients, frequently self-pay or cash-pay, growing fastest, and the segment where a structured program (initiation, titration, accountability visits) converts a one-off prescription into a multi-visit relationship.
• Complex and rare endocrine cases, adrenal, pituitary, bone metabolism, reproductive endocrine, lower volume but high clinical value and a differentiator against generalist competitors and telehealth platforms.

Quantifying each segment's size, payer profile, and acquisition cost is what turns a generic "the market is growing" claim into a forecast a lender can underwrite. The plan should show which segment converts fastest, which carries the best margin, and which can be reached most cheaply through primary-care referral relationships rather than paid acquisition.

The Competitive Picture

Competition in endocrinology rarely looks like another independent endocrinologist on the same street, because there simply are not enough of them. The real competitive set is three-layered. Hospital and academic systems hold the brand and the referral defaults but run long wait lists and impersonal scheduling, the access gap a nimble practice exploits. Primary-care physicians increasingly manage straightforward type 2 diabetes themselves, so a new practice has to be clear about which patients it wants referred and make that referral effortless. Digital platforms compete on convenience and price for the obesity-medicine and thyroid segments, which means a private practice wins by pairing the relationship and the hands-on work-up with the same online convenience for follow-ups. A plan that maps these three layers honestly, and states where the practice wins each one, reads far stronger than one that pretends it has no competition.

SBA & Practice Financing Data

Physician practices are among the more bankable small businesses an SBA 7(a) lender will see, because insured medical revenue is predictable and the failure rate is low. A startup endocrinology practice typically maps to NAICS 621111, Offices of Physicians (except Mental Health Specialists), the code your lender and your forecast should both reference.

The SBA 7(a) program lends up to $5 million with terms reaching 10 years for working capital and equipment, or up to 25 years when real estate is involved. For a practice opening in the $150,000–$500,000 band, a 7(a) loan or a $100,000+ revolving line of credit is the standard route to cover build-out and to bridge payroll until claims start paying. Many specialty lenders also offer dedicated physician-practice loans with limited or no personal-collateral requirements, pricing off the predictability of payer reimbursement rather than hard assets.

The detail most first-time owners miss is that the loan has to be sized for the credentialing gap. You can be fully licensed and still unable to bill a commercial plan for 60 to 120 days while enrollment processes. A lender wants to see that working-capital line explicitly model that gap, not a forecast that assumes revenue in month one. Our $1,000/£800 bespoke plans build the cash-flow forecast around the enrollment calendar so the loan ask matches reality.

UK founders rarely fund a clinic with a single Start Up Loan (capped at £25,000 per founder at 6% fixed), but it is a useful first tranche stacked with consultant savings, a commercial bank facility, or a partnership where two or three clinicians pool capital and share sessions. Whichever route you choose, lenders read the same three things first: the credentialing timeline, the patient-acquisition plan, and a forecast that survives a slow first quarter.

A practical structure many endocrinology owners use is to split the raise into two parts: a term loan covering the one-time build-out and equipment, and a revolving line of credit sized to the credentialing gap and seasonal swings. The term loan amortizes against assets the lender can value; the line of credit absorbs the months where payroll runs ahead of collections. Presenting the ask this way, rather than as one large lump sum, signals to a lender that you understand the difference between capital expenditure and working capital, and it usually produces better pricing because the risk on each tranche is clearer.

What It Costs to Open the Doors

Opening an endocrinology practice generally runs $90,000 to $500,000 in the US, or roughly £70,000 to £380,000 in the UK. The spread is wide because the model choices are wide: a lease-light clinic that sends labs to a hospital and runs telehealth follow-ups opens near the floor, while a fully built consulting suite with on-site DXA bone-density imaging and a full clinical team sits near the ceiling (Fullscript, 2025).

Where the Money Goes

• Premises lease deposit & clinical fit-out: $25,000–$140,000 (£18K–£90K), exam rooms, phlebotomy station, ADA/accessibility compliance
• EHR, practice management & billing software: $11,000–$55,000/yr (£8K–£40K), endocrinology-tuned platforms such as RXNT handle CGM data and insulin titration workflows
• Clinical equipment & instruments: $15,000–$120,000 (£12K–£90K), point-of-care HbA1c, specimen fridge, optional DXA scanner
• Staff recruitment (NP/PA, medical assistant, front desk): $15,000–$96,000 (£12K–£70K) initial
• Malpractice / professional indemnity: $8,000–$30,000/yr (£6K–£20K)
• Credentialing, licensing & 3–6 months working capital: $30,000–$120,000 (£20K–£90K)

The two line items first-time owners under-budget are working capital and credentialing. A practice can look fully operational, staffed, stocked, seeing patients, and still bank almost nothing for three months while payer enrollment clears. Build the plan so the bank balance can absorb a quarter of payroll before reimbursement turns on. That single discipline is the difference between a practice that reaches breakeven calmly and one that scrambles for an emergency draw in month two.

Lean Launch vs Full Build

Two endocrinology practices opening in the same city can sit $300,000 apart in startup cost purely on model choice, and the plan should make that choice explicit rather than defaulting to the most expensive version. A lean launch takes a short-term lease in existing medical space, sends labs to a hospital or reference lab, leans on telehealth for follow-ups, and starts with the physician plus one medical assistant. That model can open closer to $90,000–$150,000 and reach cash-flow positive faster, at the cost of slower in-house ancillary revenue.

A full build commits to a longer lease with a custom fit-out, in-house phlebotomy, a nurse practitioner from day one, and a roadmap to on-site thyroid ultrasound and DXA. It costs $350,000–$500,000 and carries more fixed overhead through the credentialing gap, but it captures ancillary revenue earlier and presents a more defensible, higher-ceiling practice to a future buyer or partner. Neither is "right", the plan's job is to pick one deliberately, size the loan to it, and show the lender the reasoning. Most first-time owners are better served starting lean and adding the capital-heavy ancillaries once referral volume proves them out.

Equipment & Build-Out Checklist

Endocrinology is light on heavy machinery compared with a surgical or imaging specialty, which is part of what keeps the entry cost reachable. The capital you do spend should track patient volume, not ambition. Here is a realistic price-banded list for a solo-to-small practice.

• EHR + practice management suite (annual): $11,000–$55,000, endocrine-specific platforms (e.g. RXNT) integrate CGM downloads, insulin-pump data and lab flowsheets
• Point-of-care HbA1c analyzer: $1,500–$4,000 plus per-test cartridges, drives same-visit decisions and a small in-house revenue line
• Continuous glucose monitor (CGM) reader / clinic kit: $0–$3,000, many vendors supply readers free; revenue comes from interpretation, not the device
• Specimen refrigerator & centrifuge: $2,000–$8,000, for on-site draw, spin and ship if you do not co-locate with a lab
• Exam-room furnishing (per room): $4,000–$9,000, table, scale with stadiometer, BP, lockable storage
• Thyroid ultrasound (optional, mid-stage): $20,000–$60,000, add once nodule volume justifies in-house FNA workflow
• DXA bone-density scanner (optional, later): $35,000–$90,000, only when osteoporosis volume supports it; outsource until then
• Crash cart, glucagon & emergency kit: $1,500–$4,000, required for hypoglycemia and contrast reactions

The discipline here is sequencing. A common error is buying a DXA scanner on day one because it is the most "endocrinology" piece of kit in the catalog. Outsource bone density and thyroid ultrasound until referral volume makes the machine pay for itself; the same capital is far better deployed as working capital through the credentialing gap.

How the Practice Makes Money

Most endocrinology revenue is evaluation-and-management billing, office visits, coded by complexity. The workhorse code for an established patient is CPT 99214, reimbursed by Medicare at a national non-facility average of about $135.61 on the CY 2026 schedule, with commercial plans typically paying $160–$220 depending on contract (TheraThink, 2026). Endocrinology runs heavily toward 99214 rather than 99213 because chronic diabetes and thyroid management genuinely meets moderate-complexity criteria, and coding it accurately is worth roughly $40 a visit over chronic under-coding.

A Worked Example

Take a solo endocrinologist seeing 18 established patients a day at a blended $150 per 99214-level visit, working 4.5 clinical days a week across about 46 weeks. That is roughly $558,000 a year in office E/M revenue before any ancillary lines. Layer in CGM interpretation (CPT 95249/95251) and remote patient monitoring (CPT 99457) for the diabetes panel, plus in-house point-of-care testing, and gross collections commonly land in the $620,000–$720,000 range. After a typical 62% overhead load, staff, rent, malpractice, software, supplies, the practice nets in the region of $210,000–$250,000 to the owner.

The recurring-revenue layer is what separates a comfortable practice from a fragile one. CGM interpretation and remote monitoring turn a panel of diabetes patients into predictable monthly billing rather than visit-by-visit income, and they smooth the cash flow that a lender most wants to see. A structured obesity-medicine line built around GLP-1 therapy, initiation visits, titration follow-ups, and accountability check-ins, adds a second recurring stream that many practices still treat as an afterthought.

It is worth being concrete about how those ancillary lines compound. A diabetes panel of 300 patients on continuous glucose monitors, billed for interpretation and remote monitoring, can add a five-figure recurring monthly layer on top of office visits, revenue that arrives whether or not the patient has an appointment that month. That is precisely the kind of predictable, between-visit income a lender underwrites with confidence, and it is the reason a plan that models ancillary revenue separately reads stronger than one that buries everything in a single per-visit average. The obesity-medicine line behaves similarly: a patient starting GLP-1 therapy typically returns for several titration and review visits over the first six months, so each new start is a short series of billable encounters rather than a one-off script.

In the UK, a private consultant model prices differently: a first consultation typically runs £200–£300 with follow-ups at £150–£200 (GoPrivate / PrivateHealth.co.uk). A private clinic often blends self-pay with insurer panels (Bupa, AXA Health, Vitality) and a sessional model where the consultant rents clinic space rather than carrying a full lease, a leaner structure that suits a part-NHS, part-private career.

Reading the Margin Honestly

The 12–28% net-margin band is real, but it hides a wide gap between a well-run practice and a poorly sequenced one. Overhead in a specialty office is dominated by labour: clinical and front-office staff usually account for 25–35% of collections, with rent, malpractice, software, and supplies filling out the rest of the 55–65% overhead load. The single biggest lever a new owner controls is not price, payer contracts are largely fixed, but throughput and coding accuracy. A schedule that runs at 80% capacity with clean 99214 coding and active ancillary billing earns a margin a half-empty schedule with defensive under-coding never reaches, even at identical patient counts.

The second lever is payer mix. A panel weighted toward commercial plans (paying $160–$220 for a 99214) carries a materially better blended rate than a Medicare-heavy panel (about $135.61), and a self-pay obesity-medicine line sidesteps payer contracts entirely. A forecast that states its assumed payer mix and shows how it shifts as the practice matures is the version a lender trusts. One that quotes a single average reimbursement without saying where it came from is the version they question.

Licensing, Credentialing & Compliance

For an endocrinology practice the regulatory work is less about a single "license to open" and more about a sequence of credentialing steps, each with its own clock. Getting the order right is the difference between billing in month one and waiting until month four.

United States

• State medical license in the state of practice, an active, unrestricted license is the gate to everything else
• National Provider Identifier (NPI) via NPPES, the 10-digit number behind every Medicare and Medicaid claim, issued within days
• Medicare enrollment through PECOS, CMS-855B for the group practice, CMS-855I for the physician; clean applications clear in 30–90 days via a Medicare Administrative Contractor
• Commercial payer credentialing via CAQH ProView, attest the file, authorize each target payer; expect 60–120 days per plan
• DEA registration + state controlled-substance license, essential for insulin-adjacent and testosterone prescribing
• HIPAA compliance, malpractice cover, and CLIA if you run any in-house lab testing such as point-of-care HbA1c

Running Medicare and commercial credentialing in parallel rather than in sequence reduces total time-to-billing by 45 to 60 days (Neolytix, 2026). The plan should put this on a calendar, because every week of delay is a week of fixed costs without revenue.

United Kingdom

• GMC registration with a licence to practise, and in most cases entry on the GMC Specialist Register in endocrinology and diabetes to work as a consultant
• Care Quality Commission (CQC) registration under the "Treatment of Disease, Disorder or Injury" regulated activity, legally required before a private clinic sees patients; allow roughly 10–14 weeks
• Medical indemnity through a defence organisation (MDU, MPS) or commercial insurer, typically £6,000–£20,000 a year for private endocrinology
• Information Commissioner's Office (ICO) registration and UK GDPR compliance for patient data

One Other Jurisdiction

In Australia, a consultant endocrinologist needs AHPRA specialist registration with FRACP recognition through the Royal Australasian College of Physicians, plus a Medicare provider number to deliver rebated consultations. In the UAE, licensing is by emirate, DHA in Dubai, DOH in Abu Dhabi, MOH elsewhere, and requires both a personal practitioner licence and a separate facility licence, with most private clinics joining insurer panels such as Daman alongside self-pay.

Across every jurisdiction the planning lesson is the same: licensing is a sequence, not a switch. The narrative plan should hold a dated credentialing timeline next to the cash-flow forecast so the two move together. The fastest way to turn a profitable concept into a distressed one is to commit to a lease and a payroll before the enrollments that pay for them have cleared.

Endocrinology Practice Terms a Lender Will Expect You to Use

Part of looking credible to a bank or a partner is using the operating vocabulary of the specialty correctly. These are the terms that recur throughout a strong endocrinology plan:

• PECOS, the Provider Enrollment, Chain, and Ownership System, the CMS portal used to enroll the practice and physician with Medicare via the CMS-855 forms.
• CAQH ProView, the universal credentialing database commercial payers draw from; you attest the file and authorize each plan you want to join.
• CPT 99214, the moderate-complexity established-patient office visit that forms the revenue backbone of a chronic-disease specialty like endocrinology.
• CGM interpretation (95249 / 95251), billing for setting up and reading continuous glucose monitor data, a recurring ancillary line for the diabetes panel.
• RPM (99457), remote patient monitoring, the code behind monthly between-visit management of connected diabetes patients.
• NAICS 621111, the industry code (Offices of Physicians) your SBA application and financial forecast should reference.
• Payer mix, the proportion of collections coming from Medicare, commercial plans, and self-pay; the single biggest driver of blended reimbursement.
• Credentialing gap, the 60–120 day window between opening and being able to bill a payer, and the line your working-capital reserve has to cover.

Five Costly Mistakes to Avoid

Endocrinology practices rarely fail on clinical quality. They stumble on the business mechanics that a plan is meant to pre-empt. The clinician is usually excellent at the medicine and underprepared for the cash-flow timing, the coding discipline, and the capital sequencing, exactly the areas a lender scrutinizes hardest. These five errors appear again and again in real launches, and a good plan neutralizes each one before the first patient is booked.

• Opening before credentialing clears. Seeing commercial patients you cannot yet bill creates 60–120 days of unpaid visits. Sequence the launch around enrollment, not the lease date.
• Chronic under-coding to 99213. Endocrine chronic management usually qualifies as moderate complexity (99214). Defaulting low can quietly cost roughly $40 a visit, which across a full panel is tens of thousands a year.
• Ignoring recurring ancillary revenue. CGM interpretation (95249/95251) and remote patient monitoring (99457) turn a diabetes panel into monthly billing. Practices that skip them leave predictable cash on the table.
• Buying a DXA scanner too early. A $35K–$90K machine bought before nodule and osteoporosis volume exists is dead capital. Outsource imaging until referral flow justifies it.
• Treating GLP-1 prescribing as a favour, not a service line. The obesity-medicine wave is a structured program, initiation, titration, accountability, not a loss-leading add-on. Price and staff it deliberately.

Sample Business Plan Preview

The strongest endocrinology plans read like an operating document, not a brochure. They name the patient lines, the payer mix, the credentialing calendar, and the working-capital reserve in numbers a lender can test. Here is an extract from an endocrinology practice plan written by our team, so you can see the level of specificity a lender or partner expects:

What's in the Template

Every Avvale business plan template is pre-structured for your specialty. The endocrinology version includes prompts and worked examples for each of these sections:

• Executive Summary, your practice, patient lines and funding ask in a page a banker reads in 60 seconds
• Clinical & Service Model, diabetes, thyroid and obesity-medicine lines, telehealth mix, and panel-growth assumptions
• Market & Access Analysis, local wait-list data, referral sources, and the endocrinologist-shortage tailwind in your catchment
• Patient & Referral Strategy, primary-care referral pipelines, self-pay obesity-medicine acquisition, and retention
• Competitor Mapping, hospital systems, other private endocrinologists, and digital platforms such as Paloma Health or Steady Health
• Operations & Credentialing Plan, the PECOS/CAQH timeline mapped against your cash position
• Staffing Model, physician, NP/PA, medical assistant and billing roles with ramp assumptions
• Financial Forecast, CPT-coded revenue build, overhead load, and a working-capital bridge through credentialing

The Financial Forecast add-on (included in our $300/£250 and $1,000/£800 packages) provides a 5-year Excel model with income statement, cash flow, balance sheet, break-even analysis, and a credentialing-aware working-capital schedule, the version SBA lenders and practice partners actually ask to see. Each line is built from the same CPT-coded revenue logic and payer-mix assumptions laid out above, so the narrative and the numbers tell one consistent story rather than two that a reviewer has to reconcile.

Frequently Asked Questions

Related Templates & Resources

Building out a different healthcare venture, or want to compare structures before you commit? These Avvale resources pair well with this guide:

• Free business plan templates, the full library across industries
• Market research & content service, done-for-you research and narrative
• Medical clinic business plan template, for a broader multi-specialty or primary-care build
• Avvale case studies, real funded plans across healthcare and beyond